Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel
Chronic hepatitis C (HCV) infection is currently one of the most clinically relevant comorbidities in the HIV population; overall, it affects one third of HIV-positive individuals. Progression to end-stage liver disease occurs faster in coinfected patients and decompensated cirrhosis is one of the m...
Saved in:
| Published in | AIDS (London) Vol. 21; no. 9; pp. 1073 - 1089 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Hagerstown, MD
Lippincott Williams & Wilkins
31.05.2007
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Chronic hepatitis C (HCV) infection is currently one of the most clinically relevant comorbidities in the HIV population; overall, it affects one third of HIV-positive individuals. Progression to end-stage liver disease occurs faster in coinfected patients and decompensated cirrhosis is one of the main causes of hospitalization and death in this population. However, the risk of hepatotoxicity using antiretroviral drugs is increased in subjects with underlying HCV infection. Therefore, the optimal management of chronic HCV in HIV-positive patients is currently a priority. |
|---|---|
| AbstractList | Chronic hepatitis C (HCV) infection is currently one of the most clinically relevant comorbidities in the HIV population; overall, it affects one third of HIV-positive individuals. Progression to end-stage liver disease occurs faster in coinfected patients and decompensated cirrhosis is one of the main causes of hospitalization and death in this population. However, the risk of hepatotoxicity using antiretroviral drugs is increased in subjects with underlying HCV infection. Therefore, the optimal management of chronic HCV in HIV-positive patients is currently a priority. |
| Author | Bräu, Norbert Pol, Stanislas Sulkowski, Mark Cargnel, Antonietta Rockstroh, Juergen Puoti, Massimo Soriano, Vincent Hatzakis, Angelos Benhamou, Yves Peters, Marion Mauss, Stefan |
| Author_xml | – sequence: 1 givenname: Vincent surname: Soriano fullname: Soriano, Vincent – sequence: 2 givenname: Massimo surname: Puoti fullname: Puoti, Massimo – sequence: 3 givenname: Mark surname: Sulkowski fullname: Sulkowski, Mark – sequence: 4 givenname: Antonietta surname: Cargnel fullname: Cargnel, Antonietta – sequence: 5 givenname: Yves surname: Benhamou fullname: Benhamou, Yves – sequence: 6 givenname: Marion surname: Peters fullname: Peters, Marion – sequence: 7 givenname: Stefan surname: Mauss fullname: Mauss, Stefan – sequence: 8 givenname: Norbert surname: Bräu fullname: Bräu, Norbert – sequence: 9 givenname: Angelos surname: Hatzakis fullname: Hatzakis, Angelos – sequence: 10 givenname: Stanislas surname: Pol fullname: Pol, Stanislas – sequence: 11 givenname: Juergen surname: Rockstroh fullname: Rockstroh, Juergen |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18837985$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17502718$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkc1u1DAUhb0ooj_wBgh5A7sp13H8110VfmakSoAE3UaOfaMxSpzBdopYwTvwhjwJmXYAqQtYXFlX_s7R1Tmn5ChOEQl5wuCcgVEv3l--PIcOGEdeaQa6xtofkROopFkZruCYnOb8CQAEaP2QHDMloFJMn5BvjU1Ip57ubAkYS6ZuCrFHV9DTL6Fs6XpzTW30dIt7pIRMG3oT0pwvaAWg6Lzzdg8ndNM4Yly2MMVM-zSNtGyRrpvrn99_7G02sWCKt_92oO9sxOERedDbIePjw3tGPr5-9aFZr67evtk0l1crx6UsK-EkE7L2SnBnuFCwjKk7JyrsvDVOeS2VlrZWna8rLXtmuFbO97KywJdgzsjzO99dmj7PmEs7huxwGJYjpjm3CgTjRvH_ghUDwZU0C_j0AM7diL7dpTDa9LX9ne0CPDsANjs79MlGF_JfTmuujBYLd3HHuTTlnLBvXSi3IZVkw9AyaPclt0vJ7f2SF3F9T_zH_1-yX-DErJE |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0025753 crossref_primary_10_1517_14656566_2010_500615 crossref_primary_10_1093_jac_dkr215 crossref_primary_10_1016_j_addbeh_2011_12_010 crossref_primary_10_54393_pbmj_v5i4_380 crossref_primary_10_1007_s11901_009_0015_9 crossref_primary_10_1016_j_eimc_2010_03_002 crossref_primary_10_1016_j_cgh_2008_11_019 crossref_primary_10_1093_infdis_jir754 crossref_primary_10_1186_s12879_015_1224_1 crossref_primary_10_1016_j_antiviral_2011_02_013 crossref_primary_10_1017_S0950268812002397 crossref_primary_10_1097_MEG_0b013e328341ef54 crossref_primary_10_1111_jvh_12041 crossref_primary_10_1177_135965350801300303 crossref_primary_10_1111_jvh_12180 crossref_primary_10_9778_cmajo_20130009 crossref_primary_10_1097_MPG_0b013e318258328d crossref_primary_10_1111_j_1365_2893_2008_01015_x crossref_primary_10_1093_cid_cit221 crossref_primary_10_1007_s11904_010_0071_3 crossref_primary_10_1177_039493620802001_208 crossref_primary_10_2217_17460794_2_5_437 crossref_primary_10_1016_j_eimc_2012_03_006 crossref_primary_10_1111_j_1365_2893_2010_01334_x crossref_primary_10_1186_s12889_017_4769_7 crossref_primary_10_3109_00952990_2010_540280 crossref_primary_10_1007_s11904_013_0169_5 crossref_primary_10_1111_j_1468_1293_2007_00535_x crossref_primary_10_1086_588669 crossref_primary_10_1007_s10096_014_2245_1 crossref_primary_10_1016_j_coviro_2014_04_011 crossref_primary_10_1111_hiv_12105 crossref_primary_10_1186_1471_2334_14_150 crossref_primary_10_1016_j_bpg_2011_02_012 crossref_primary_10_1097_QAD_0b013e3283391d6d crossref_primary_10_1592_phco_31_4_357 crossref_primary_10_1590_S0004_28032009000200011 crossref_primary_10_1038_clpt_2008_110 crossref_primary_10_3851_IMP2757 crossref_primary_10_1089_aid_2007_0240 crossref_primary_10_1111_j_1365_2036_2009_04004_x crossref_primary_10_1016_S0399_8320_09_72445_5 crossref_primary_10_1097_QAD_0b013e3282fbd203 crossref_primary_10_1016_S1473_3099_15_00485_5 crossref_primary_10_1089_aid_2011_0096 crossref_primary_10_1590_1678_4685_GMB_2015_0106 crossref_primary_10_1111_j_1365_2893_2010_01299_x crossref_primary_10_1097_QAI_0b013e3181f9c0b6 crossref_primary_10_1016_j_clim_2008_03_521 crossref_primary_10_1586_14787210_5_5_769 crossref_primary_10_1097_QAD_0b013e32835f5b9c crossref_primary_10_12998_wjcc_v9_i18_4491 crossref_primary_10_1111_jvh_12519 crossref_primary_10_3389_fmicb_2021_780887 crossref_primary_10_1093_cid_ciu698 crossref_primary_10_1097_QAD_0b013e3283036cac crossref_primary_10_1016_S1473_3099_09_70264_6 crossref_primary_10_1097_QAD_0b013e32835ce2c1 crossref_primary_10_1017_S0950268814000041 crossref_primary_10_1097_QAD_0b013e3283350f7c crossref_primary_10_1002_hep_23959 crossref_primary_10_1016_S0213_005X_08_76522_4 crossref_primary_10_1093_jac_dkr093 crossref_primary_10_2217_17584310_3_1_87 crossref_primary_10_1097_QAI_0b013e31816de85f crossref_primary_10_1111_apt_14577 crossref_primary_10_1310_hct1301_33 crossref_primary_10_3851_IMP1843 crossref_primary_10_1093_jac_dkn175 crossref_primary_10_18821_0507_4088_2016_61_1_34_39 crossref_primary_10_1002_jmv_23407 crossref_primary_10_1111_j_1365_2362_2011_02623_x crossref_primary_10_1016_S1730_1270_10_60044_6 crossref_primary_10_1097_FPC_0000000000000158 crossref_primary_10_1097_COH_0b013e3282f0fd8d crossref_primary_10_1310_hct0905_348 crossref_primary_10_1517_14740338_2015_1019461 crossref_primary_10_4137_SART_S580 crossref_primary_10_4254_wjh_v8_i31_1295 crossref_primary_10_1016_j_antib_2008_08_004 crossref_primary_10_1111_jvh_12120 crossref_primary_10_1053_j_gastro_2009_09_053 crossref_primary_10_1097_QAI_0b013e31821fdee2 crossref_primary_10_1111_hiv_12033 crossref_primary_10_1016_S1665_2681_19_31807_1 crossref_primary_10_1517_14656566_9_7_1197 crossref_primary_10_1007_s11901_010_0080_0 crossref_primary_10_1016_j_meegid_2018_02_034 crossref_primary_10_1097_COH_0b013e3282f0aadd crossref_primary_10_2217_pgs_2018_0046 crossref_primary_10_3350_cmh_2014_20_2_89 crossref_primary_10_1086_605292 crossref_primary_10_3851_IMP2703 crossref_primary_10_1111_j_1365_2893_2009_01260_x crossref_primary_10_1097_QAD_0b013e3283471d83 crossref_primary_10_1016_j_cld_2013_07_007 crossref_primary_10_1016_j_yapd_2016_04_019 crossref_primary_10_1177_135965350701203S06 crossref_primary_10_1016_j_jhep_2007_10_006 crossref_primary_10_1093_jac_dkr091 crossref_primary_10_1111_j_1440_1746_2008_05489_x crossref_primary_10_15789_2220_7619_2013_4_371_375 crossref_primary_10_1016_j_cld_2008_03_009 crossref_primary_10_1016_j_cld_2009_11_007 crossref_primary_10_3851_IMP1861 crossref_primary_10_1155_2014_493087 crossref_primary_10_1111_j_1365_2893_2011_01570_x crossref_primary_10_3748_wjg_v24_i5_613 crossref_primary_10_1093_cid_cis500 crossref_primary_10_1016_j_jcv_2014_08_020 crossref_primary_10_1177_135965350801300404 crossref_primary_10_1186_s12916_014_0198_y crossref_primary_10_3109_00365540903214272 crossref_primary_10_1089_aid_2009_0120 crossref_primary_10_1016_j_eimc_2013_04_009 crossref_primary_10_1097_QAI_0b013e3181b62858 crossref_primary_10_1590_S0004_28032013000100005 crossref_primary_10_1016_j_bjid_2012_09_009 crossref_primary_10_1007_s10620_011_1841_5 crossref_primary_10_1093_jac_dkp446 crossref_primary_10_1016_j_jinf_2013_10_011 crossref_primary_10_1016_j_ijid_2008_05_091 crossref_primary_10_1016_j_jinf_2012_02_014 crossref_primary_10_1111_j_1365_2893_2012_01624_x crossref_primary_10_1093_jac_dkp447 crossref_primary_10_1093_jac_dkr506 crossref_primary_10_1007_s11908_012_0313_1 crossref_primary_10_1186_s12879_015_1291_3 crossref_primary_10_1097_QAI_0b013e3181bd5ce1 crossref_primary_10_1111_j_1365_2893_2007_00939_x crossref_primary_10_1177_135965350801300818 crossref_primary_10_1097_QAD_0b013e32835c11e8 crossref_primary_10_1517_13543784_16_8_1171 crossref_primary_10_1111_j_1872_034X_2009_00608_x crossref_primary_10_1310_hct1303_142 crossref_primary_10_1097_QAD_0b013e3282f8b46f crossref_primary_10_1111_j_1365_2036_2012_05145_x crossref_primary_10_1310_hct1001_52 crossref_primary_10_1093_infdis_jir113 crossref_primary_10_1016_j_jinf_2015_09_013 crossref_primary_10_2217_17584310_3_2_189 crossref_primary_10_1089_apc_2018_0006 crossref_primary_10_1093_infdis_jis449 crossref_primary_10_1590_S0036_46652008000400005 crossref_primary_10_1007_s15010_008_7319_5 crossref_primary_10_3851_IMP1492 crossref_primary_10_1177_135965350801300709 crossref_primary_10_22625_2072_6732_2018_10_4_6_13 crossref_primary_10_2217_hiv_10_29 crossref_primary_10_1016_j_jhep_2007_11_009 crossref_primary_10_3390_v10060293 crossref_primary_10_1016_j_clinthera_2012_07_011 crossref_primary_10_1177_1049732311418248 crossref_primary_10_1093_cid_cir446 crossref_primary_10_1016_S0399_8320_09_72452_2 crossref_primary_10_3947_ic_2011_43_2_89 crossref_primary_10_1186_1471_2288_8_25 crossref_primary_10_1371_journal_pone_0101441 crossref_primary_10_1007_s11845_011_0746_9 crossref_primary_10_1310_hct0901_43 crossref_primary_10_1016_j_idc_2012_08_004 crossref_primary_10_1038_nbt1364 crossref_primary_10_2217_17460794_2_4_319 crossref_primary_10_1016_S1155_1976_08_46513_0 crossref_primary_10_1111_j_1365_2893_2009_01133_x crossref_primary_10_1177_135965350701200805 crossref_primary_10_1056_NEJMcpc0910091 crossref_primary_10_1007_s11901_007_0012_9 crossref_primary_10_3851_IMP1708 crossref_primary_10_1097_COH_0b013e3282f0dce1 crossref_primary_10_1016_S0399_8320_09_72449_2 crossref_primary_10_1016_j_jhep_2013_04_005 crossref_primary_10_1097_QAD_0b013e32834bbb90 crossref_primary_10_1016_j_jcv_2012_05_012 crossref_primary_10_1093_jac_dkr385 crossref_primary_10_3109_10408363_2013_865702 crossref_primary_10_1002_jmv_22026 crossref_primary_10_3851_IMP1831 crossref_primary_10_1007_s11901_012_0143_5 crossref_primary_10_1097_QAD_0b013e32833c11a5 crossref_primary_10_1097_QCO_0b013e32835c2027 crossref_primary_10_1002_hep_25616 crossref_primary_10_1097_QAD_0b013e3282f1da99 crossref_primary_10_1016_j_eimc_2011_02_009 crossref_primary_10_1007_s11901_013_0179_1 crossref_primary_10_1186_s12879_014_0577_1 crossref_primary_10_1111_j_1365_2893_2009_01215_x crossref_primary_10_1097_QAD_0b013e3283480144 crossref_primary_10_1111_j_1365_2036_2008_03718_x crossref_primary_10_1097_MD_0000000000016376 crossref_primary_10_1016_j_dld_2013_09_001 crossref_primary_10_1097_QAD_0000000000000005 crossref_primary_10_1016_j_cld_2011_05_006 crossref_primary_10_1016_j_jhep_2015_06_034 crossref_primary_10_1517_14656566_2012_653341 crossref_primary_10_1157_13126270 crossref_primary_10_1016_S1413_8670_10_70050_7 crossref_primary_10_1016_j_cld_2010_09_012 crossref_primary_10_1093_cid_ciw379 crossref_primary_10_1177_1545109708330906 crossref_primary_10_1371_journal_pone_0143836 crossref_primary_10_1016_j_epidem_2015_04_001 crossref_primary_10_3389_fimmu_2017_01461 crossref_primary_10_1089_apc_2007_0216 crossref_primary_10_1111_j_1478_3231_2012_02796_x crossref_primary_10_1089_apc_2010_0342 crossref_primary_10_1097_QAD_0b013e3282f7067e crossref_primary_10_1016_j_idc_2014_05_005 crossref_primary_10_1186_1742_6405_11_16 crossref_primary_10_1016_j_eimc_2011_07_003 crossref_primary_10_1007_s15010_012_0353_3 crossref_primary_10_2217_fvl_13_61 crossref_primary_10_1002_hep_25647 crossref_primary_10_1111_j_1365_2893_2010_01309_x crossref_primary_10_1016_j_antiviral_2009_10_021 crossref_primary_10_1111_j_1365_2893_2008_00969_x crossref_primary_10_1517_14728214_13_1_1 crossref_primary_10_1097_QAD_0b013e3283471cae crossref_primary_10_1186_s12879_019_3974_7 crossref_primary_10_1097_QAI_0b013e31824f5506 crossref_primary_10_1007_s10461_012_0288_9 crossref_primary_10_1016_j_jcv_2015_02_004 crossref_primary_10_1097_QAD_0b013e3283389e26 crossref_primary_10_1186_s12879_016_1422_5 crossref_primary_10_1086_592171 crossref_primary_10_1093_jac_dkn420 crossref_primary_10_1093_jac_dkn421 crossref_primary_10_1111_j_1365_2893_2009_01180_x crossref_primary_10_1016_j_eimc_2010_12_001 crossref_primary_10_2165_00151234_200705310_00003 crossref_primary_10_1093_infdis_jir194 crossref_primary_10_1016_j_clinre_2015_04_001 crossref_primary_10_1038_ajg_2009_726 crossref_primary_10_1016_j_bpg_2012_09_007 crossref_primary_10_1155_2012_973627 crossref_primary_10_1097_QAD_0000000000000275 crossref_primary_10_3109_08923973_2014_971962 crossref_primary_10_5812_hepatmon_8611 crossref_primary_10_1097_QAD_0b013e32833eacfd crossref_primary_10_1586_eri_12_107 |
| Cites_doi | 10.1097/00002030-200012220-00011 10.1016/S0140-6736(00)03618-7 10.1002/hep.20563 10.1177/135965350501000217 10.1097/01.aids.0000226956.02719.fd 10.1016/S0140-6736(04)15997-7 10.1046/j.1365-2893.2003.00413.x 10.1097/01.qai.0000170034.90438.68 10.1053/jhep.2001.26511 10.1111/j.1365-2893.2005.00580.x 10.1016/S0168-8278(06)80577-5 10.1001/jama.283.1.74 10.1097/00002030-200401020-00007 10.1053/j.gastro.2004.11.018 10.1002/hep.20073 10.1097/01.qai.0000174649.51084.46 10.1136/gut.2005.069153 10.1097/00002030-200107060-00007 10.1002/hep.20506 10.1097/01.qai.0000192005.08153.a3 10.1097/01.qai.0000167158.90722.73 10.1097/00002030-200008180-00025 10.2165/00002018-200528010-00004 10.1097/01.aids.0000198087.47454.e1 10.1111/j.1572-0241.2005.00222.x 10.1016/j.jhep.2005.10.003 10.1016/j.jhep.2005.07.006 10.1086/317491 10.1053/jhep.2003.50107 10.1002/lt.20498 10.1097/00042560-200205010-00008 10.1056/NEJMoa011232 10.7326/0003-4819-123-5-199509010-00002 10.7326/0003-4819-140-5-200403020-00010 10.1056/NEJMoa032653 10.1177/135965350501000512 10.1053/j.gastro.2006.05.016 10.1002/hep.20944 10.1056/NEJM200210173471623 10.1111/j.1365-2893.2005.00667.x 10.1001/jama.292.23.2839 10.1097/01.qai.0000221683.44940.62 10.1097/00002030-200401020-00009 10.1002/hep.20107 10.1097/00002030-200201250-00020 10.1002/hep.510230607 10.1016/j.jhep.2005.10.019 10.1097/00002030-200305020-00011 10.1097/00002030-199710001-00003 10.1097/00002030-200211220-00033 10.1111/j.1365-2893.2004.00519.x 10.1053/j.gastro.2006.01.034 10.1310/FRWE-HCGF-K3BG-DG8P 10.1086/428093 10.1089/aid.1998.14.1661 10.1053/jhep.2002.30319 10.1056/NEJMoa042608 10.1053/jhep.2002.36128 10.1177/135965350601100509 10.1007/s15010-004-3080-6 10.1016/j.jhep.2005.02.025 10.1086/380130 10.1310/R7B4-Q37L-FAQ7-LQB7 10.1111/j.1440-1746.2005.03791.x 10.1097/00002030-200303280-00015 10.1056/NEJMoa040842 10.1086/425360 10.1016/S1590-8658(00)80850-6 10.1097/00002030-200401020-00008 10.1111/j.1365-2893.2005.00683.x 10.1053/gast.2002.35950 10.1016/j.jhep.2005.11.032 10.1097/01.qai.0000191281.77954.27 10.1089/aid.2006.22.139 10.1097/01.qai.0000192001.15777.15 10.1016/S0016-5085(99)70402-6 10.1016/S0168-8278(06)80738-5 10.1097/00007691-200010000-00010 10.1310/N4VT-3E9U-4BKN-CRPW 10.1056/NEJM200107053450107 10.1053/j.gastro.2004.09.050 10.1111/j.1468-1293.2006.00365.x 10.1086/318501 10.1016/j.jhep.2005.11.028 10.1177/135965350400900108 10.1097/00002030-200303280-00010 10.1097/00002030-200409030-00003 10.1053/jhep.2003.50096 10.1002/hep.510300409 10.1053/jhep.2003.09022 10.1136/bmj.38050.593634.63 10.1016/S0168-8278(06)80745-2 10.1097/00002030-200411190-00009 10.1177/135965350400900616 10.1016/S0168-8278(06)80599-4 10.1016/S0140-6736(03)14844-1 10.1111/j.1365-2893.2005.00685.x 10.1111/j.1572-0241.2002.06038.x 10.1016/S0168-8278(06)80734-8 10.1097/00042560-200201010-00005 10.1053/gast.1996.v110.pm8536854 10.1016/S0140-6736(06)69155-1 10.1016/S0016-5085(00)70145-4 10.1002/hep.21178 10.1111/j.1468-1293.2005.00300.x 10.1177/135965350501000410 10.1097/01.aids.0000247584.46567.64 10.1177/135965350400900411 10.1016/S0168-8278(06)80012-7 10.1089/088922204323048096 10.1136/gut.2005.065904 10.1001/jama.284.4.450 10.1177/135965350501000111 10.1002/hep.510270333 10.1016/j.jhep.2005.04.008 10.7326/0003-4819-133-9-200011070-00008 10.1053/jhep.2001.28458 10.1016/S0168-8278(03)00018-7 10.1097/01.aids.0000180787.10553.b2 10.1097/01.qai.0000174930.64145.a9 10.1097/00002030-200411190-00008 10.1097/01.qai.0000184856.31695.bf 10.1097/00126334-200301010-00005 10.1016/S0168-8278(06)80009-7 10.1097/00126334-200310010-00006 10.1097/00002030-199810000-00025 10.1097/00002030-200308150-00009 10.7326/0003-4819-137-1-200207020-00006 10.1177/135965350400900604 10.1016/j.jhep.2004.12.004 10.1053/j.gastro.2004.01.014 10.1016/S0168-8278(02)00101-0 10.1056/NEJM199906033402215 10.1016/j.jhep.2004.08.008 10.1097/00002030-200204120-00001 10.1097/00002030-200401020-00001 10.1111/j.1365-2893.2005.00651.x 10.1086/426021 10.1086/512679 10.1097/00002030-200409030-00002 10.1086/379255 10.1016/S0168-8278(99)80020-8 10.1056/NEJMoa020047 10.1089/aid.2006.22.333 10.1086/432762 10.1111/j.1468-1293.2004.00225.x 10.1053/j.gastro.2006.02.015 10.1086/427216 10.1053/j.gastro.2004.01.027 10.1016/S0168-8278(06)80564-7 10.1016/j.jhep.2005.07.003 10.1089/aid.2005.21.555 10.1093/jac/dkl074 10.1053/j.gastro.2004.11.059 10.1086/429496 10.1086/379254 10.1002/hep.20814 10.1097/00002030-200410210-00008 10.1177/135965350601100409 10.1016/j.jhep.2005.03.003 10.1016/S0168-8278(06)80506-4 10.1016/S0016-5085(03)00668-1 10.7326/0003-4819-137-12-200212170-00009 10.1086/501021 10.1053/j.gastro.2006.02.037 10.1128/AAC.49.10.3997-4008.2005 10.1038/nature03153 10.1089/08892220152644160 10.1089/aid.2006.22.315 10.1086/367643 10.1053/jhep.2000.16602 10.1097/QAD.0b013e328012b5d3 10.1001/jama.288.2.199 10.1097/00126334-200108150-00002 10.1177/135965350501000215 10.1086/317644 10.1016/j.hepres.2004.03.007 10.1111/j.1468-1293.2004.00239.x 10.1016/S0168-8278(98)80177-3 10.1053/j.gastro.2004.12.049 10.1097/01.qai.0000194238.15831.c7 |
| ContentType | Journal Article |
| Copyright | 2007 INIST-CNRS |
| Copyright_xml | – notice: 2007 INIST-CNRS |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 7U9 H94 7X8 |
| DOI | 10.1097/QAD.0b013e3281084e4d |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EndPage | 1089 |
| ExternalDocumentID | 17502718 18837985 10_1097_QAD_0b013e3281084e4d |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- .XZ .Z2 01R 0R~ 1J1 23M 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ 85S 8L- AAAAV AAAXR AAGIX AAIQE AAJCS AAMOA AAMTA AARTV AASOK AAUEB AAXQO AAYXX ABBUW ABDIG ABIVO ABJNI ABPXF ABXVJ ABZAD ACCJW ACDDN ACDOF ACEWG ACGFS ACILI ACOAL ACWDW ACWRI ACXNZ ACZKN ADBBV ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFDTB AFEXH AFFNX AFNMH AFUWQ AGINI AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW ALKUP ALMA_UNASSIGNED_HOLDINGS AMJPA AMNEI BAWUL BOYCO BQLVK BYPQX C45 CITATION CS3 DIK DIWNM DUNZO E.X E3Z EBS EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 H0~ HZ~ IKREB IKYAY IN~ JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B O9- OAG OAH OBH OCUKA ODMTH OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OPX ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWU OWV OWW OWX OWY OWZ OXXIT P2P RLZ S4R S4S SJN TEORI TR2 V2I VVN W3M WOQ WOW X3V X3W XJT XXN XYM YFH ZZMQN .GJ 1CY AAHPQ AAQKA AASCR AASXQ ABASU ABVCZ ABXYN ABZZY ACIJW ACLDA ACXJB ADFPA AEBDS AFBFQ AFMBP AFSOK AHQVU AKCTQ AKULP ALMTX AMKUR AOHHW AOQMC BS7 CAG COF EEVPB EJD ERAAH GNXGY GQDEL HLJTE IPNFZ IQODW N4W N~M ODA P-K R58 RIG T8P TSPGW UAP ZGI ZXP AWKKM CGR CUY CVF ECM EIF NPM OJAPA OLW 7T5 7U9 H94 7X8 |
| ID | FETCH-LOGICAL-c366t-5c61564d753c9357035794bc52ebda9c7d86786a47bd4286f19387cdf62a03013 |
| ISSN | 0269-9370 |
| IngestDate | Fri Jul 11 03:26:07 EDT 2025 Fri Jul 11 05:39:14 EDT 2025 Wed Feb 19 02:09:41 EST 2025 Wed Apr 02 07:25:09 EDT 2025 Thu Apr 24 22:59:53 EDT 2025 Tue Jul 01 00:40:03 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | Immunopathology Mixed infection liver Cytokine Hepatic disease AIDS Immune deficiency Recommendation Ribavirin Infection Virus HIV Viral disease Nucleoside analog Digestive diseases Antiviral Interferon HCV Flaviviridae Hepatitis C virus Hepacivirus Viral hepatitis C |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c366t-5c61564d753c9357035794bc52ebda9c7d86786a47bd4286f19387cdf62a03013 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Review-3 |
| PMID | 17502718 |
| PQID | 21053769 |
| PQPubID | 23462 |
| PageCount | 17 |
| ParticipantIDs | proquest_miscellaneous_70513973 proquest_miscellaneous_21053769 pubmed_primary_17502718 pascalfrancis_primary_18837985 crossref_citationtrail_10_1097_QAD_0b013e3281084e4d crossref_primary_10_1097_QAD_0b013e3281084e4d |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2007-05-31 |
| PublicationDateYYYYMMDD | 2007-05-31 |
| PublicationDate_xml | – month: 05 year: 2007 text: 2007-05-31 day: 31 |
| PublicationDecade | 2000 |
| PublicationPlace | Hagerstown, MD |
| PublicationPlace_xml | – name: Hagerstown, MD – name: England |
| PublicationTitle | AIDS (London) |
| PublicationTitleAlternate | AIDS |
| PublicationYear | 2007 |
| Publisher | Lippincott Williams & Wilkins |
| Publisher_xml | – name: Lippincott Williams & Wilkins |
| References | Rodriguez-Torres (R180-1-20210130) 2005; 49 Puoti (R20-1-20210130) 2000; 32 Moreno (R83-1-20210130) 2004; 18 Puoti (R211-1-20210130) 2001; 183 Sulkowski (R10-1-20210130) 2000; 283 Margot (R177-1-20210130) 2005; 10 Ballesteros (R82-1-20210130) 2004; 18 Lenzo (R186-1-20210130) 1997; 11 Grando-Lemaire (R63-1-20210130) 2006; 44 Wong (R44-1-20210130) 2000; 133 Nuñez (R9-1-20210130) 2001; 27 Vogel (R152-1-20210130) 2005; 12 Alberti (R25-1-20210130) 2002; 137 Torriani (R88-1-20210130) 2003; 188 Zeuzem (R112-1-20210130) 2006; 44 Ferenci (R111-1-20210130) 2006; 44 Niro (R172-1-20210130) 2006; 44 Sanchez-Tapias (R120-1-20210130) 2006; 131 Buti (R118-1-20210130) 2003; 37 Soriano (R76-1-20210130) 2006; 44 Sulkowski (R198-1-20210130) 2002; 35 Myers (R49-1-20210130) 2003; 17 Jen (R95-1-20210130) 2000; 22 Shakil (R18-1-20210130) 1995; 123 Desmond (R90-1-20210130) 2006; 13 Laguno (R84-1-20210130) 2004; 18 Patel (R51-1-20210130) 2004; 41 Moreno (R174-1-20210130) 2004; 9 Ghosn (R139-1-20210130) 2004; 5 Wyles (R134-1-20210130) 2005; 40 De Ledinghen (R57-1-20210130) 2006; 41 Rendon (R96-1-20210130) 2005; 39 Perez-Olmeda (R97-1-20210130) 2003; 17 Parkes (R54-1-20210130) 2006; 44 Ziol (R46-1-20210130) 2005; 4 Martínez-Sierra (R4-1-20210130) 2003; 36 Shindo (R17-1-20210130) 1995; 22 Brau (R213-1-20210130) 2006; 44 Hung (R167-1-20210130) 2005; 20 De Pouplana (R159-1-20210130) 1995; 71 Bonacini (R164-1-20210130) 2004; 18 Par (R128-1-20210130) 2006; 44 Martinez (R201-1-20210130) 2001; 15 Sim (R178-1-20210130) 1998; 14 Myers (R124-1-20210130) 2004; 18 Piroth (R193-1-20210130) 2005; 7 Soriano (R86-1-20210130) 2004; 9 Sterling (R53-1-20210130) 2006; 43 Benhamou (R2-1-20210130) 1999; 30 Batisse (R196-1-20210130) 2002; 16 Qurishi (R210-1-20210130) 2003; 362 Merchante (R133-1-20210130) 2006; 20 Anderson (R154-1-20210130) 2004; 39 Chariot (R185-1-20210130) 1999; 30 Gebo (R8-1-20210130) 2003; 34 Sulkowski (R155-1-20210130) 2002; 288 Kim (R24-1-20210130) 2004; 328 Alberti (R40-1-20210130) 2005; 42 Jardi (R157-1-20210130) 2001; 34 Puoti (R165-1-20210130) 2006; 11 Nunes (R56-1-20210130) 2005; 40 McHutchison (R91-1-20210130) 2006; 44 Nuñez (R183-1-20210130) 2005; 28 Nuñez (R194-1-20210130) 2002; 30 Alberti (R12-1-20210130) 2005; 42 Regev (R43-1-20210130) 2002; 97 Soriano (R59-1-20210130) 2003; 17 Martin-Carbonero (R199-1-20210130) 2003; 4 Zeuzem (R39-1-20210130) 2004; 127 Barreiro (R60-1-20210130) 2006; 42 Rockstroh (R1-1-20210130) 2005; 192 Sulkowski (R79-1-20210130) 2005; 39 Liu (R166-1-20210130) 2003; 37 Chuang (R168-1-20210130) 2005; 10 Shiffman (R106-1-20210130) 2006; 44 Macias (R55-1-20210130) 2006; 55 Luetkemeyer (R142-1-20210130) 2006; 41 Nuñez (R161-1-20210130) 2005; 6 Mangia (R105-1-20210130) 2005; 352 Foucher (R61-1-20210130) 2006; 55 Fried (R80-1-20210130) 2002; 347 Colletta (R48-1-20210130) 2005; 42 Prati (R23-1-20210130) 2002; 137 Andriulli (R58-1-20210130) 2004; 11 Puoti (R171-1-20210130) 1998; 29 Forns (R50-1-20210130) 2002; 36 Tien (R14-1-20210130) 2005; 100 Lissen (R126-1-20210130) 2006; 20 McHutchison (R75-1-20210130) 2002; 123 Bani-Dadr (R70-1-20210130) 2006; 44 Sagnelli (R162-1-20210130) 2004; 32 Carrat (R68-1-20210130) 2004; 292 Santin (R100-1-20210130) 2006; 22 Puoti (R27-1-20210130) 2003; 38 Bani-Sadr (R132-1-20210130) 2005; 40 Sanchez-Conde (R175-1-20210130) 2005; 6 Rodriguez-Rosado (R190-1-20210130) 1998; 12 Fuster (R122-1-20210130) 2006; 11 Maida (R30-1-20210130) 2006; 22 Merchante (R209-1-20210130) 2006; 20 Lafeuillade (R173-1-20210130) 2001; 357 Chung (R85-1-20210130) 2004; 351 Chakvetadze (R169-1-20210130) 2007; 21 Nuñez (R94-1-20210130) 2005; 10 Soriano (R113-1-20210130) 2004; 20 de Ledhingen (R64-1-20210130) 2006; 44 Aceti (R191-1-20210130) 2002; 29 Eron (R205-1-20210130) 2006; 368 Hopkins (R115-1-20210130) 2006; 7 Soriano (R11-1-20210130) 2002; 16 Saito (R45-1-20210130) 2004; 29 Berg (R119-1-20210130) 2006; 130 Fonquernie (R29-1-20210130) 2004; 5 Mathurin (R28-1-20210130) 1998; 27 Fontana (R121-1-20210130) 2006; 130 Sulkowski (R188-1-20210130) 2000; 283 Bedossa (R42-1-20210130) 2003; 38 Den Brinker (R192-1-20210130) 2000; 14 Yano (R36-1-20210130) 1996; 23 Gonzalez de Requena (R203-1-20210130) 2005; 21 Dubé (R72-1-20210130) 2000; 31 Prati (R19-1-20210130) 1996; 110 Hadziyannis (R104-1-20210130) 2004; 140 Gonzalez de Requena (R202-1-20210130) 2002; 16 Lindahl (R93-1-20210130) 2005; 41 Soriano (R170-1-20210130) 2007; 195 Bica (R6-1-20210130) 2001; 32 Regev (R66-1-20210130) 2002; 97 Martin-Carbonero (R3-1-20210130) 2004; 38 de Mendoza (R182-1-20210130) 2005; 10 Rosenthal (R7-1-20210130) 2003; 17 Velasco (R189-1-20210130) 1999; 340 Laguno (R77-1-20210130) 2004; 9 Torriani (R67-1-20210130) 2004; 351 Soriano (R89-1-20210130) 2004; 9 Sherman (R87-1-20210130) 2005; 128 Maida (R197-1-20210130) 2006; 42 Arribas (R156-1-20210130) 2005; 19 Persico (R22-1-20210130) 2000; 118 Persico (R37-1-20210130) 2006; 13 van Leth (R200-1-20210130) 2004; 363 Castera (R47-1-20210130) 2005; 128 Marcellin (R110-1-20210130) 2006; 44 Landau (R179-1-20210130) 2000; 14 Dominguez (R147-1-20210130) 2006; 20 Cadranel (R41-1-20210130) 2000; 32 Sulkowski (R204-1-20210130) 2004; 18 Vogel (R137-1-20210130) 2005; 11 Martin-Carbonero (R5-1-20210130) 2001; 17 Martinot-Peignoux (R21-1-20210130) 2001; 34 Garcia-Benayas (R181-1-20210130) 2002; 347 Perelson (R102-1-20210130) 2005; 43 Puoti (R26-1-20210130) 2002; 37 Voigt (R98-1-20210130) 2005; 51 Cargnel (R99-1-20210130) 2005; 10 Jaeckel (R150-1-20210130) 2001; 345 Pineda (R207-1-20210130) 2006; 57 Camma (R127-1-20210130) 2004; 39 Sanne (R187-1-20210130) 2005; 191 Ragni (R138-1-20210130) 2003; 188 Neff (R136-1-20210130) 2005; 41 Okanoue (R34-1-20210130) 2005; 43 Thomas (R146-1-20210130) 2000; 284 Tural (R214-1-20210130) 2003; 10 Mauss (R131-1-20210130) 2004; 18 Garcia-Benayas (R73-1-20210130) 2006; 22 Ratziu (R74-1-20210130) 2006; 44 Kelleher (R52-1-20210130) 2005; 43 Gilleece (R143-1-20210130) 2005; 40 Afdhal (R78-1-20210130) 2004; 126 Romero-Gomez (R71-1-20210130) 2005; 128 Dixit (R103-1-20210130) 2004; 432 Shiffman (R129-1-20210130) 1999; 117 Brau (R108-1-20210130) 2004; 39 Miro (R135-1-20210130) 2006; 44 Torti (R195-1-20210130) 2006; 41 Soriano (R130-1-20210130) 2006; 20 Aranzabal (R65-1-20210130) 2005; 40 Shiffman (R125-1-20210130) 2004; 126 Micallef (R145-1-20210130) 2006; 13 Uberti-Foppa (R33-1-20210130) 2006; 41 Boccato (R38-1-20210130) 2006; 13 Silini (R16-1-20210130) 1995; 21 Kamal (R149-1-20210130) 2006; 130 Puoti (R163-1-20210130) 2004; 18 Gerlach (R148-1-20210130) 2003; 125 Raimondo (R158-1-20210130) 2006; 43 Sterling (R35-1-20210130) 2003; 32 Soriano (R15-1-20210130) 2004; 18 McHutchison (R107-1-20210130) 2002; 123 Nelson (R13-1-20210130) 2005; 6 Lauer (R32-1-20210130) 2001; 345 McGovern (R184-1-20210130) 2004; 3 |
| References_xml | – volume: 14 start-page: 2895 year: 2000 ident: R192-1-20210130 article-title: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection publication-title: AIDS doi: 10.1097/00002030-200012220-00011 – volume: 357 start-page: 280 year: 2001 ident: R173-1-20210130 article-title: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection publication-title: Lancet doi: 10.1016/S0140-6736(00)03618-7 – volume: 41 start-page: 275 year: 2005 ident: R93-1-20210130 article-title: High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C publication-title: Hepatology doi: 10.1002/hep.20563 – volume: 10 start-page: 343 year: 2005 ident: R177-1-20210130 article-title: In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1 publication-title: Antivir Ther doi: 10.1177/135965350501000217 – volume: 20 start-page: 1157 year: 2006 ident: R147-1-20210130 article-title: Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients publication-title: AIDS doi: 10.1097/01.aids.0000226956.02719.fd – volume: 363 start-page: 1253 year: 2004 ident: R200-1-20210130 article-title: Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study publication-title: Lancet doi: 10.1016/S0140-6736(04)15997-7 – volume: 10 start-page: 118 year: 2003 ident: R214-1-20210130 article-title: Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus co-infected patients publication-title: J Viral Hepat doi: 10.1046/j.1365-2893.2003.00413.x – volume: 39 start-page: 401 year: 2005 ident: R96-1-20210130 article-title: Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000170034.90438.68 – volume: 34 start-page: 404 year: 2001 ident: R157-1-20210130 article-title: Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference publication-title: Hepatology doi: 10.1053/jhep.2001.26511 – volume: 12 start-page: 207 year: 2005 ident: R152-1-20210130 article-title: Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2005.00580.x – volume: 44 start-page: 214 issue: suppl 2 year: 2006 ident: R63-1-20210130 article-title: Liver stiffness measurement as a tool to measure liver fibrosis in treated patients with chronic hepatitis C publication-title: J Hepatol doi: 10.1016/S0168-8278(06)80577-5 – volume: 283 start-page: 74 year: 2000 ident: R188-1-20210130 article-title: Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection publication-title: JAMA doi: 10.1001/jama.283.1.74 – volume: 18 start-page: 59 year: 2004 ident: R82-1-20210130 article-title: Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV coinfection: indications for the investigation of new treatment approaches publication-title: AIDS doi: 10.1097/00002030-200401020-00007 – volume: 21 start-page: 285 year: 1995 ident: R16-1-20210130 article-title: Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities publication-title: Hepatology – volume: 128 start-page: 343 year: 2005 ident: R47-1-20210130 article-title: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.11.018 – volume: 39 start-page: 333 year: 2004 ident: R127-1-20210130 article-title: Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data publication-title: Hepatology doi: 10.1002/hep.20073 – volume: 20 start-page: 2225 year: 2006 ident: R130-1-20210130 article-title: Regression of liver fibrosis in hepatitis C virus/HIV-coinfected patients following treatment with pegylated interferon plus ribavirin publication-title: AIDS – volume: 40 start-page: 47 year: 2005 ident: R132-1-20210130 article-title: Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000174649.51084.46 – volume: 55 start-page: 310 year: 2006 ident: R61-1-20210130 article-title: Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study publication-title: Gut doi: 10.1136/gut.2005.069153 – volume: 15 start-page: 1261 year: 2001 ident: R201-1-20210130 article-title: Hepatotoxicity in HIV-infected patients receiving nevirapine-containing antiretroviral therapy publication-title: AIDS doi: 10.1097/00002030-200107060-00007 – volume: 4 start-page: 48 year: 2005 ident: R46-1-20210130 article-title: Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C publication-title: Hepatology doi: 10.1002/hep.20506 – volume: 41 start-page: 180 year: 2006 ident: R195-1-20210130 article-title: Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER cohort publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000192005.08153.a3 – volume: 39 start-page: 504 year: 2005 ident: R79-1-20210130 article-title: Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000167158.90722.73 – volume: 14 start-page: 1857 year: 2000 ident: R179-1-20210130 article-title: Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy publication-title: AIDS doi: 10.1097/00002030-200008180-00025 – volume: 28 start-page: 53 year: 2005 ident: R183-1-20210130 article-title: Hepatotoxicity of antiretrovirals: incidence, mechanisms and management publication-title: Drug Saf doi: 10.2165/00002018-200528010-00004 – volume: 20 start-page: 49 year: 2006 ident: R133-1-20210130 article-title: Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease publication-title: AIDS doi: 10.1097/01.aids.0000198087.47454.e1 – volume: 100 start-page: 2338 year: 2005 ident: R14-1-20210130 article-title: Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Program publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2005.00222.x – volume: 44 start-page: 97 year: 2006 ident: R112-1-20210130 article-title: Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre-treatment viremia publication-title: J Hepatol doi: 10.1016/j.jhep.2005.10.003 – volume: 44 start-page: 47 year: 2006 ident: R213-1-20210130 article-title: Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy publication-title: J Hepatol doi: 10.1016/j.jhep.2005.07.006 – volume: 31 start-page: 1467 year: 2000 ident: R72-1-20210130 article-title: Disorders of glucose metabolism in patients infected with HIV publication-title: Clin Infect Dis doi: 10.1086/317491 – volume: 37 start-page: 1226 year: 2003 ident: R118-1-20210130 article-title: Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases publication-title: Hepatology doi: 10.1053/jhep.2003.50107 – volume: 11 start-page: 1515 year: 2005 ident: R137-1-20210130 article-title: Orthotopic liver transplantation inHIV-positive patients: outcome of 7 patients from the Bonn cohort publication-title: Liver Transpl doi: 10.1002/lt.20498 – volume: 30 start-page: 65 year: 2002 ident: R194-1-20210130 article-title: Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy publication-title: J Acquir Immun Defic Syndr doi: 10.1097/00042560-200205010-00008 – volume: 345 start-page: 1452 year: 2001 ident: R150-1-20210130 article-title: Treatment of acute hepatitis C with interferon alfa-2b publication-title: N Engl J Med doi: 10.1056/NEJMoa011232 – volume: 123 start-page: 330 year: 1995 ident: R18-1-20210130 article-title: Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features publication-title: Ann Intern Med doi: 10.7326/0003-4819-123-5-199509010-00002 – volume: 140 start-page: 346 year: 2004 ident: R104-1-20210130 article-title: Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose publication-title: Ann Intern Med doi: 10.7326/0003-4819-140-5-200403020-00010 – volume: 351 start-page: 451 year: 2004 ident: R85-1-20210130 article-title: Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons publication-title: N Engl J Med doi: 10.1056/NEJMoa032653 – volume: 10 start-page: 657 year: 2005 ident: R94-1-20210130 article-title: Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C publication-title: Antivir Ther doi: 10.1177/135965350501000512 – volume: 131 start-page: 451 year: 2006 ident: R120-1-20210130 article-title: Peginterferon alfa-2a plus ribavirin for 72 weeks in chronic hepatitis C patients without a response by week 4 publication-title: Gastroenterology doi: 10.1053/j.gastro.2006.05.016 – volume: 43 start-page: 100 year: 2006 ident: R158-1-20210130 article-title: Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients publication-title: Hepatology doi: 10.1002/hep.20944 – volume: 347 start-page: 1287 year: 2002 ident: R181-1-20210130 article-title: Weight loss in HIV-infected patients publication-title: N Engl J Med doi: 10.1056/NEJM200210173471623 – volume: 13 start-page: 290 year: 2006 ident: R37-1-20210130 article-title: Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2005.00667.x – volume: 292 start-page: 2839 year: 2004 ident: R68-1-20210130 article-title: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.292.23.2839 – volume: 42 start-page: 177 year: 2006 ident: R197-1-20210130 article-title: Severe liver disease associated with prolonged exposure to antiretroviral drugs publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000221683.44940.62 – volume: 18 start-page: 75 year: 2004 ident: R124-1-20210130 article-title: Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy publication-title: AIDS doi: 10.1097/00002030-200401020-00009 – volume: 39 start-page: 989 year: 2004 ident: R108-1-20210130 article-title: Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b + ribavirin full-course vs 16-week delayed ribavirin publication-title: Hepatology doi: 10.1002/hep.20107 – volume: 16 start-page: 290 year: 2002 ident: R202-1-20210130 article-title: Liver toxicity caused by nevirapine publication-title: AIDS doi: 10.1097/00002030-200201250-00020 – volume: 23 start-page: 1334 year: 1996 ident: R36-1-20210130 article-title: The long-term pathological evolution of chronic hepatitis C publication-title: Hepatology doi: 10.1002/hep.510230607 – volume: 44 start-page: 462 year: 2006 ident: R54-1-20210130 article-title: Performance of serum marker panels for liver fibrosis in chronic hepatitis C publication-title: J Hepatol doi: 10.1016/j.jhep.2005.10.019 – volume: 17 start-page: 1023 year: 2003 ident: R97-1-20210130 article-title: Pegylated IFN-alpha 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients publication-title: AIDS doi: 10.1097/00002030-200305020-00011 – volume: 11 start-page: 1294 year: 1997 ident: R186-1-20210130 article-title: Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report publication-title: AIDS doi: 10.1097/00002030-199710001-00003 – volume: 16 start-page: 2370 year: 2002 ident: R196-1-20210130 article-title: Severe liver mitochondriopathy with normal liver histology and normal lactate levels in patients receiving nucleoside analogues publication-title: AIDS doi: 10.1097/00002030-200211220-00033 – volume: 11 start-page: 536 year: 2004 ident: R58-1-20210130 article-title: Treatment of patients with HCV infection with or without liver biopsy publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2004.00519.x – volume: 130 start-page: 632 year: 2006 ident: R149-1-20210130 article-title: Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response publication-title: Gastroenterology doi: 10.1053/j.gastro.2006.01.034 – volume: 6 start-page: 278 year: 2005 ident: R175-1-20210130 article-title: Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin publication-title: HIV Clin Trials doi: 10.1310/FRWE-HCGF-K3BG-DG8P – volume: 191 start-page: 825 year: 2005 ident: R187-1-20210130 article-title: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects publication-title: J Infect Dis doi: 10.1086/428093 – volume: 14 start-page: 1661 year: 1998 ident: R178-1-20210130 article-title: Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.1998.14.1661 – volume: 35 start-page: 182 year: 2002 ident: R198-1-20210130 article-title: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections publication-title: Hepatology doi: 10.1053/jhep.2002.30319 – volume: 352 start-page: 2609 year: 2005 ident: R105-1-20210130 article-title: Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3 publication-title: N Engl J Med doi: 10.1056/NEJMoa042608 – volume: 36 start-page: 986 year: 2002 ident: R50-1-20210130 article-title: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model publication-title: Hepatology doi: 10.1053/jhep.2002.36128 – volume: 11 start-page: 576 year: 2006 ident: R165-1-20210130 article-title: Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis publication-title: Antivir Ther doi: 10.1177/135965350601100509 – volume: 32 start-page: 144 year: 2004 ident: R162-1-20210130 article-title: Influence of chronic coinfection with hepatitis B and C virus on liver histology publication-title: Infection doi: 10.1007/s15010-004-3080-6 – volume: 43 start-page: 78 year: 2005 ident: R52-1-20210130 article-title: Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index publication-title: J Hepatol doi: 10.1016/j.jhep.2005.02.025 – volume: 38 start-page: 128 year: 2004 ident: R3-1-20210130 article-title: Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C: a European collaborative study publication-title: Clin Infect Dis doi: 10.1086/380130 – volume: 6 start-page: 103 year: 2005 ident: R161-1-20210130 article-title: Hepatitis C viremia in HIV/HCV-coinfected patients: lower levels in presence of chronic hepatitis B publication-title: HIV Clin Trials doi: 10.1310/R7B4-Q37L-FAQ7-LQB7 – volume: 20 start-page: 727 year: 2005 ident: R167-1-20210130 article-title: Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2005.03791.x – volume: 17 start-page: 751 year: 2003 ident: R59-1-20210130 article-title: Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? publication-title: AIDS doi: 10.1097/00002030-200303280-00015 – volume: 351 start-page: 438 year: 2004 ident: R67-1-20210130 article-title: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients publication-title: N Engl J Med doi: 10.1056/NEJMoa040842 – volume: 39 start-page: 1507 year: 2004 ident: R154-1-20210130 article-title: Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study publication-title: Clin Infect Dis doi: 10.1086/425360 – volume: 32 start-page: 634 year: 2000 ident: R20-1-20210130 article-title: Hepatitis C carriers with normal aminotransferase levels: healthy people or true patients? publication-title: Digest Liver Dis doi: 10.1016/S1590-8658(00)80850-6 – volume: 18 start-page: 67 year: 2004 ident: R83-1-20210130 article-title: Pegylated interferon-a2b + ribavirin for the treatment of chronic hepatitis C in HIV-infected patients publication-title: AIDS doi: 10.1097/00002030-200401020-00008 – volume: 13 start-page: 297 year: 2006 ident: R38-1-20210130 article-title: Fibrosis progression in initially mild chronic hepatitis C publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2005.00683.x – volume: 123 start-page: 1061 year: 2002 ident: R75-1-20210130 article-title: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C publication-title: Gastroenterology doi: 10.1053/gast.2002.35950 – volume: 44 start-page: 44 issue: suppl 1 year: 2006 ident: R76-1-20210130 article-title: Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates publication-title: J Hepatol doi: 10.1016/j.jhep.2005.11.032 – volume: 41 start-page: 31 year: 2006 ident: R142-1-20210130 article-title: Clinical presentation and course of acute hepatitis C infection in HIV-infected patients publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000191281.77954.27 – volume: 22 start-page: 139 year: 2006 ident: R30-1-20210130 article-title: Liver enzyme elevation in hepatitis C virus (HCV)–HIV co-infected patients prior to and after initiating HAART: role of HCV genotypes publication-title: AIDS Res Human Retroviruses doi: 10.1089/aid.2006.22.139 – volume: 41 start-page: 63 year: 2006 ident: R33-1-20210130 article-title: Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000192001.15777.15 – volume: 117 start-page: 1164 year: 1999 ident: R129-1-20210130 article-title: A randomised, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C and persistent viremia publication-title: Gastroenterology doi: 10.1016/S0016-5085(99)70402-6 – volume: 44 start-page: 272 issue: suppl 2 year: 2006 ident: R74-1-20210130 article-title: A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in NASH; results of the FLIRT pilot trial publication-title: J Hepatol doi: 10.1016/S0168-8278(06)80738-5 – volume: 22 start-page: 555 year: 2000 ident: R95-1-20210130 article-title: Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C publication-title: Ther Drug Monit doi: 10.1097/00007691-200010000-00010 – volume: 4 start-page: 115 year: 2003 ident: R199-1-20210130 article-title: Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine publication-title: HIV Clin Trials doi: 10.1310/N4VT-3E9U-4BKN-CRPW – volume: 345 start-page: 41 year: 2001 ident: R32-1-20210130 article-title: Hepatitis C virus infection publication-title: N Engl J Med doi: 10.1056/NEJM200107053450107 – volume: 127 start-page: 1724 year: 2004 ident: R39-1-20210130 article-title: Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.09.050 – volume: 7 start-page: 248 year: 2006 ident: R115-1-20210130 article-title: Role of individualization of HCV therapy duration in HIV/HCV-coinfected individuals publication-title: HIV Med doi: 10.1111/j.1468-1293.2006.00365.x – volume: 32 start-page: 492 year: 2001 ident: R6-1-20210130 article-title: Increasing mortality due to end-stage liver disease in patients with HIV infection publication-title: Clin Infect Dis doi: 10.1086/318501 – volume: 44 start-page: 140 issue: suppl year: 2006 ident: R135-1-20210130 article-title: Management of end stage liver disease: what is the current role of orthotopic liver transplantation? publication-title: J Hepatol doi: 10.1016/j.jhep.2005.11.028 – volume: 9 start-page: 133 year: 2004 ident: R174-1-20210130 article-title: High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin publication-title: Antivir Ther doi: 10.1177/135965350400900108 – volume: 17 start-page: 721 year: 2003 ident: R49-1-20210130 article-title: Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients publication-title: AIDS doi: 10.1097/00002030-200303280-00010 – volume: 18 start-page: F27 year: 2004 ident: R84-1-20210130 article-title: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients publication-title: AIDS doi: 10.1097/00002030-200409030-00003 – volume: 37 start-page: 568 year: 2003 ident: R166-1-20210130 article-title: Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients publication-title: Hepatology doi: 10.1053/jhep.2003.50096 – volume: 30 start-page: 1054 year: 1999 ident: R2-1-20210130 article-title: Liver fibrosis progression in HIV and hepatitis C virus coinfected patients publication-title: Hepatology doi: 10.1002/hep.510300409 – volume: 38 start-page: 1449 year: 2003 ident: R42-1-20210130 article-title: Sampling variability of liver fibrosis in chronic hepatitis C publication-title: Hepatology doi: 10.1053/jhep.2003.09022 – volume: 328 start-page: 983 year: 2004 ident: R24-1-20210130 article-title: Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study publication-title: Br Med J doi: 10.1136/bmj.38050.593634.63 – volume: 44 start-page: 275 issue: suppl 2 year: 2006 ident: R91-1-20210130 article-title: Sustained virologic response to interferon alpha-2b ± ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5 year follow-up publication-title: J Hepatol doi: 10.1016/S0168-8278(06)80745-2 – volume: 18 start-page: 2285 year: 2004 ident: R163-1-20210130 article-title: Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome publication-title: AIDS doi: 10.1097/00002030-200411190-00009 – volume: 9 start-page: 987 year: 2004 ident: R89-1-20210130 article-title: Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies publication-title: Antivir Ther doi: 10.1177/135965350400900616 – volume: 44 start-page: 222 issue: suppl 2 year: 2006 ident: R128-1-20210130 article-title: Peg-IFN plus ribavirin therapy suppresses plasma TGF-1 beta, hyaluronic acid and procollagen-III peptide levels in patients with chronic hepatitis C independently of virological response publication-title: J Hepatol doi: 10.1016/S0168-8278(06)80599-4 – volume: 362 start-page: 1708 year: 2003 ident: R210-1-20210130 article-title: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection publication-title: Lancet doi: 10.1016/S0140-6736(03)14844-1 – volume: 13 start-page: 290 year: 2006 ident: R90-1-20210130 article-title: Sustained virologic response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2005.00685.x – volume: 51 start-page: 245 year: 2005 ident: R98-1-20210130 article-title: Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV coinfected patients publication-title: J Infect – volume: 97 start-page: 2614 year: 2002 ident: R66-1-20210130 article-title: Sampling error and intra-observer variation in liver biopsy in patients with chronic HCV infection publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2002.06038.x – volume: 44 start-page: 271 issue: suppl 2 year: 2006 ident: R106-1-20210130 article-title: Peginterferon alpha-2a plus ribavirin for 16 or 24 weeks in patients with HCV genotypes 2 or 3. Final results of the ACCELERATE trial publication-title: J Hepatol doi: 10.1016/S0168-8278(06)80734-8 – volume: 29 start-page: 41 year: 2002 ident: R191-1-20210130 article-title: Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. The role of hepatitis B and C virus infection publication-title: J Acquir Immun Defic Syndr doi: 10.1097/00042560-200201010-00005 – volume: 110 start-page: 178 year: 1996 ident: R19-1-20210130 article-title: Influence of different hepatitis C virus genotypes on the course of asymptomatic hepatitis C virus infection publication-title: Gastroenterology doi: 10.1053/gast.1996.v110.pm8536854 – volume: 368 start-page: 476 year: 2006 ident: R205-1-20210130 article-title: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(06)69155-1 – volume: 118 start-page: 760 year: 2000 ident: R22-1-20210130 article-title: Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels publication-title: Gastroenterology doi: 10.1016/S0016-5085(00)70145-4 – volume: 43 start-page: 1317 year: 2006 ident: R53-1-20210130 article-title: Development of a simple non-invasive index to predict significant fibrosis in patients with HIV/HCV coinfection publication-title: Hepatology doi: 10.1002/hep.21178 – volume: 6 start-page: 96 issue: suppl 2 year: 2005 ident: R13-1-20210130 article-title: BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus publication-title: HIV Med doi: 10.1111/j.1468-1293.2005.00300.x – volume: 10 start-page: 557 year: 2005 ident: R182-1-20210130 article-title: Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin publication-title: Antivir Ther doi: 10.1177/135965350501000410 – volume: 20 start-page: 2175 year: 2006 ident: R126-1-20210130 article-title: Histological response to peginterferon alfa-2a (40 kDa) plus ribavirin in HIV-HCV co-infection: Results of APRICOT publication-title: AIDS doi: 10.1097/01.aids.0000247584.46567.64 – volume: 9 start-page: 505 year: 2004 ident: R86-1-20210130 article-title: Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin publication-title: Antivir Ther doi: 10.1177/135965350400900411 – volume: 44 start-page: 7 issue: suppl 2 year: 2006 ident: R110-1-20210130 article-title: Efficacy of standard dose and fixed dose induction peginterferon alpha-2a plus ribavirin among pegylated interferon alpha-2b/ribavirin non-responders: interim analysis of the REPEAT study publication-title: J Hepatol doi: 10.1016/S0168-8278(06)80012-7 – volume: 20 start-page: 351 year: 2004 ident: R113-1-20210130 article-title: Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients publication-title: AIDS Res Hum Retroviruses doi: 10.1089/088922204323048096 – volume: 55 start-page: 409 year: 2006 ident: R55-1-20210130 article-title: Prediction of liver fibrosis in HIV/hepatitis C virus coinfected patients by simple non-invasive indexes publication-title: Gut doi: 10.1136/gut.2005.065904 – volume: 284 start-page: 450 year: 2000 ident: R146-1-20210130 article-title: The natural history of hepatitis C virus infection: host, viral, and environmental factors publication-title: JAMA doi: 10.1001/jama.284.4.450 – volume: 10 start-page: 125 year: 2005 ident: R168-1-20210130 article-title: Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy publication-title: Antivir Ther doi: 10.1177/135965350501000111 – volume: 27 start-page: 868 year: 1998 ident: R28-1-20210130 article-title: Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity publication-title: Hepatology doi: 10.1002/hep.510270333 – volume: 43 start-page: 599 year: 2005 ident: R34-1-20210130 article-title: A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferases publication-title: J Hepatol doi: 10.1016/j.jhep.2005.04.008 – volume: 133 start-page: 665 year: 2000 ident: R44-1-20210130 article-title: Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis publication-title: Ann Intern Med doi: 10.7326/0003-4819-133-9-200011070-00008 – volume: 34 start-page: 1000 year: 2001 ident: R21-1-20210130 article-title: Prospective study on anti-HCV-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA publication-title: Hepatology doi: 10.1053/jhep.2001.28458 – volume: 38 start-page: 529 year: 2003 ident: R27-1-20210130 article-title: HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy publication-title: J Hepatol doi: 10.1016/S0168-8278(03)00018-7 – volume: 19 start-page: 1361 year: 2005 ident: R156-1-20210130 article-title: Single (B or C), dual (BC or BD) and triple (BCD) viral hepatitis in HIV-infected patients in Madrid, Spain publication-title: AIDS doi: 10.1097/01.aids.0000180787.10553.b2 – volume: 40 start-page: 41 year: 2005 ident: R143-1-20210130 article-title: Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000174930.64145.a9 – volume: 18 start-page: 2277 year: 2004 ident: R204-1-20210130 article-title: Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir publication-title: AIDS doi: 10.1097/00002030-200411190-00008 – volume: 40 start-page: 538 year: 2005 ident: R56-1-20210130 article-title: HIV infection does not affect the performance of non-invasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000184856.31695.bf – volume: 7 start-page: 197 year: 2005 ident: R193-1-20210130 article-title: Liver steatosis in HIV-infected patients publication-title: AIDS Rev – volume: 32 start-page: 30 year: 2003 ident: R35-1-20210130 article-title: The clinical spectrum of hepatitis C virus in HIV coinfection publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200301010-00005 – volume: 44 start-page: 6 issue: suppl 2 year: 2006 ident: R111-1-20210130 article-title: 24 week treatment regimen with peginterferon alpha-2a plus ribavirin in HCV genotype 1 or 4 ‘super-responders’ publication-title: J Hepatol doi: 10.1016/S0168-8278(06)80009-7 – volume: 34 start-page: 165 year: 2003 ident: R8-1-20210130 article-title: Hospitalization rates differ by hepatitis C status in an urban HIV cohort publication-title: J Acquir Immune Defic Syndr doi: 10.1097/00126334-200310010-00006 – volume: 123 start-page: 1061 year: 2002 ident: R107-1-20210130 article-title: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C publication-title: Gastroenterology doi: 10.1053/gast.2002.35950 – volume: 12 start-page: 1256 year: 1998 ident: R190-1-20210130 article-title: Hepatotoxicity after introduction of highly active antiretroviral therapy publication-title: AIDS doi: 10.1097/00002030-199810000-00025 – volume: 17 start-page: 1803 year: 2003 ident: R7-1-20210130 article-title: Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study) publication-title: AIDS doi: 10.1097/00002030-200308150-00009 – volume: 137 start-page: 1 year: 2002 ident: R23-1-20210130 article-title: Updated definitions of healthy ranges for serum alanine aminotransferase levels publication-title: Ann Intern Med doi: 10.7326/0003-4819-137-1-200207020-00006 – volume: 9 start-page: 905 year: 2004 ident: R77-1-20210130 article-title: Depressive symptoms after initiation of interferon therapy in HIV-infected patients with chronic hepatitis C publication-title: Antivir Ther doi: 10.1177/135965350400900604 – volume: 42 start-page: 266 year: 2005 ident: R40-1-20210130 article-title: Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanine aminotransferase levels publication-title: J Hepatol doi: 10.1016/j.jhep.2004.12.004 – volume: 126 start-page: 1015 year: 2004 ident: R125-1-20210130 article-title: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.01.014 – volume: 37 start-page: 117 year: 2002 ident: R26-1-20210130 article-title: Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers publication-title: J Hepatol doi: 10.1016/S0168-8278(02)00101-0 – volume: 340 start-page: 1765 year: 1999 ident: R189-1-20210130 article-title: Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient publication-title: N Engl J Med doi: 10.1056/NEJM199906033402215 – volume: 41 start-page: 935 year: 2004 ident: R51-1-20210130 article-title: Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients publication-title: J Hepatol doi: 10.1016/j.jhep.2004.08.008 – volume: 16 start-page: 813 year: 2002 ident: R11-1-20210130 article-title: Care of patients with chronic hepatitis C and HIV coinfection: recommendations from the HIV–HCV International Panel publication-title: AIDS doi: 10.1097/00002030-200204120-00001 – volume: 18 start-page: 1 year: 2004 ident: R15-1-20210130 article-title: Care of patients with hepatitis C and HIV co-infection. Updated recommendations from the HIV–HCV International Panel publication-title: AIDS doi: 10.1097/00002030-200401020-00001 – volume: 13 start-page: 34 year: 2006 ident: R145-1-20210130 article-title: Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies publication-title: J Viral Hepat doi: 10.1111/j.1365-2893.2005.00651.x – volume: 40 start-page: 174 year: 2005 ident: R134-1-20210130 article-title: Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction publication-title: Clin Infect Dis doi: 10.1086/426021 – volume: 22 start-page: 418 year: 1995 ident: R17-1-20210130 article-title: The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values publication-title: Hepatology – volume: 195 start-page: 1181 year: 2007 ident: R170-1-20210130 article-title: Treatment of chronic hepatitis B and/or C in HIV-infected patients with multiple viral hepatitis infections publication-title: J Infect Dis doi: 10.1086/512679 – volume: 18 start-page: F21 year: 2004 ident: R131-1-20210130 article-title: Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy publication-title: AIDS doi: 10.1097/00002030-200409030-00002 – volume: 188 start-page: 1498 year: 2003 ident: R88-1-20210130 article-title: HCV and HIV dynamics during HCV treatment in HCV/HIV coinfection publication-title: J Infect Dis doi: 10.1086/379255 – volume: 30 start-page: 156 year: 1999 ident: R185-1-20210130 article-title: Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion publication-title: J Hepatol doi: 10.1016/S0168-8278(99)80020-8 – volume: 347 start-page: 975 year: 2002 ident: R80-1-20210130 article-title: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection publication-title: N Engl J Med doi: 10.1056/NEJMoa020047 – volume: 22 start-page: 333 year: 2006 ident: R73-1-20210130 article-title: Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2006.22.333 – volume: 192 start-page: 992 year: 2005 ident: R1-1-20210130 article-title: Influence of hepatitis C on HIV disease progression and response to antiretroviral therapy publication-title: J Infect Dis doi: 10.1086/432762 – volume: 283 start-page: 74 year: 2000 ident: R10-1-20210130 article-title: Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection publication-title: JAMA doi: 10.1001/jama.283.1.74 – volume: 5 start-page: 303 year: 2004 ident: R139-1-20210130 article-title: Acute hepatitis C in HIV-infected men who have sex with men publication-title: HIV Med doi: 10.1111/j.1468-1293.2004.00225.x – volume: 130 start-page: 1086 year: 2006 ident: R119-1-20210130 article-title: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa 2a plus ribavirin publication-title: Gastroenterology doi: 10.1053/j.gastro.2006.02.015 – volume: 44 start-page: 207 issue: suppl 2 year: 2006 ident: R70-1-20210130 article-title: Risk factors for bacterial infections in HCV/HIV-coinfected patients during interferon plus ribavirin-based therapy publication-title: J Hepatol – volume: 40 start-page: 588 year: 2005 ident: R65-1-20210130 article-title: Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection publication-title: Clin Infect Dis doi: 10.1086/427216 – volume: 126 start-page: 1302 year: 2004 ident: R78-1-20210130 article-title: Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.01.027 – volume: 44 start-page: 210 issue: suppl 2 year: 2006 ident: R64-1-20210130 article-title: Evaluation of fibrosis regression using FibroScan in HCV responder patients: a prospective controlled study publication-title: J Hepatol doi: 10.1016/S0168-8278(06)80564-7 – volume: 43 start-page: 553 year: 2005 ident: R102-1-20210130 article-title: Mutagenic effects of ribavirin in vivo publication-title: J Hepatol doi: 10.1016/j.jhep.2005.07.003 – volume: 21 start-page: 555 year: 2005 ident: R203-1-20210130 article-title: Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2005.21.555 – volume: 57 start-page: 1016 year: 2006 ident: R207-1-20210130 article-title: Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkl074 – volume: 128 start-page: 313 year: 2005 ident: R87-1-20210130 article-title: Viral kinetics in hepatitis C or hepatitis C/HIV-infected patients publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.11.059 – volume: 41 start-page: 50 issue: suppl 1 year: 2005 ident: R136-1-20210130 article-title: Outcomes among patients with end-stage liver disease who are coinfected with HIV and hepatitis C virus publication-title: Clin Infect Dis doi: 10.1086/429496 – volume: 188 start-page: 1412 year: 2003 ident: R138-1-20210130 article-title: Survival of HIV-infected liver transplant recipients publication-title: J Infect Dis doi: 10.1086/379254 – volume: 42 start-page: 838 year: 2005 ident: R48-1-20210130 article-title: Value of two non-invasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases publication-title: Hepatology doi: 10.1002/hep.20814 – volume: 18 start-page: 2039 year: 2004 ident: R164-1-20210130 article-title: Survival in patients with HIV infection and viral hepatitis B or C: a cohort study publication-title: AIDS doi: 10.1097/00002030-200410210-00008 – volume: 11 start-page: 473 year: 2006 ident: R122-1-20210130 article-title: Results of a study of prolonging treatment with pegylated interferon alpha-2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response publication-title: Antivir Ther doi: 10.1177/135965350601100409 – volume: 42 start-page: 615 year: 2005 ident: R12-1-20210130 article-title: Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients publication-title: J Hepatol doi: 10.1016/j.jhep.2005.03.003 – volume: 44 start-page: 188 issue: suppl 2 year: 2006 ident: R172-1-20210130 article-title: Pegylated interferon alpha-2b monotherapy and in combination with ribavirin in chronic hepatitis delta publication-title: J Hepatol doi: 10.1016/S0168-8278(06)80506-4 – volume: 71 start-page: 132 year: 1995 ident: R159-1-20210130 article-title: More severe course of delta hepatitis in HIV-infected patients publication-title: Genitourin Med – volume: 125 start-page: 80 year: 2003 ident: R148-1-20210130 article-title: Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance publication-title: Gastroenterology doi: 10.1016/S0016-5085(03)00668-1 – volume: 20 start-page: 49 year: 2006 ident: R209-1-20210130 article-title: Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease publication-title: AIDS doi: 10.1097/01.aids.0000198087.47454.e1 – volume: 137 start-page: 961 year: 2002 ident: R25-1-20210130 article-title: Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection publication-title: Ann Intern Med doi: 10.7326/0003-4819-137-12-200212170-00009 – volume: 42 start-page: 1032 year: 2006 ident: R60-1-20210130 article-title: Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C: assessment using transient elastometry and role of HCV genotype 3 publication-title: Clin Infect Dis doi: 10.1086/501021 – volume: 130 start-page: 1357 year: 2006 ident: R121-1-20210130 article-title: Optimizing outcomes in hepatitis C: is treatment beyond 48 weeks ever justified? publication-title: Gastroenterology doi: 10.1053/j.gastro.2006.02.037 – volume: 49 start-page: 3997 year: 2005 ident: R180-1-20210130 article-title: Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with HIV-hepatitis C virus coinfection: results of a randomized clinical study publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.49.10.3997-4008.2005 – volume: 432 start-page: 922 year: 2004 ident: R103-1-20210130 article-title: Modelling how ribavirin improves interferon response rates in hepatitis C virus infection publication-title: Nature doi: 10.1038/nature03153 – volume: 97 start-page: 2614 year: 2002 ident: R43-1-20210130 article-title: Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection publication-title: Am J Gastroenterol doi: 10.1111/j.1572-0241.2002.06038.x – volume: 3 start-page: 23 issue: suppl 2 year: 2004 ident: R184-1-20210130 article-title: Hepatic safety and HAART publication-title: J IAPAC (International Association of Physicians in AIDS Care) – volume: 17 start-page: 1467 year: 2001 ident: R5-1-20210130 article-title: Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients publication-title: AIDS Res Hum Retroviruses doi: 10.1089/08892220152644160 – volume: 22 start-page: 315 year: 2006 ident: R100-1-20210130 article-title: Efficacy and safety of pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2006.22.315 – volume: 36 start-page: 491 year: 2003 ident: R4-1-20210130 article-title: Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV publication-title: Clin Infect Dis doi: 10.1086/367643 – volume: 32 start-page: 477 year: 2000 ident: R41-1-20210130 article-title: Practices of liver biopsy in France: results of a prospective nationwide survey publication-title: Hepatology doi: 10.1053/jhep.2000.16602 – volume: 21 start-page: 393 year: 2007 ident: R169-1-20210130 article-title: Reactivation of hepatitis B virus replication during peginterferon-ribavirin therapy in an HIV/hepatitis C virus-co-infected patient with isolated anti-hepatitis B core antibodies publication-title: AIDS doi: 10.1097/QAD.0b013e328012b5d3 – volume: 288 start-page: 199 year: 2002 ident: R155-1-20210130 article-title: Hepatitis C and progression of HIV disease publication-title: JAMA doi: 10.1001/jama.288.2.199 – volume: 27 start-page: 426 year: 2001 ident: R9-1-20210130 article-title: Risk factors for severe hepatic injury following the introduction of HAART publication-title: J Acquir Immun Defic Syndr doi: 10.1097/00126334-200108150-00002 – volume: 10 start-page: 309 year: 2005 ident: R99-1-20210130 article-title: Open, randomized, multicentre Italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART publication-title: Antivir Ther doi: 10.1177/135965350501000215 – volume: 183 start-page: 134 year: 2001 ident: R211-1-20210130 article-title: Liver fibrosis progression is related to CD4+ cell depletion in patients with hepatitis C and HIV coinfection publication-title: J Infect Dis doi: 10.1086/317644 – volume: 29 start-page: 97 year: 2004 ident: R45-1-20210130 article-title: Efficacy of non-invasive elastometry on staging of hepatic fibrosis publication-title: Hepatol Res doi: 10.1016/j.hepres.2004.03.007 – volume: 5 start-page: 385 year: 2004 ident: R29-1-20210130 article-title: Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients. publication-title: HIV Med doi: 10.1111/j.1468-1293.2004.00239.x – volume: 29 start-page: 45 year: 1998 ident: R171-1-20210130 article-title: Treatment of chronic hepatitis D with interferon alpha-2b in patients with HIV infection publication-title: J Hepatol doi: 10.1016/S0168-8278(98)80177-3 – volume: 128 start-page: 636 year: 2005 ident: R71-1-20210130 article-title: Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients publication-title: Gastroenterology doi: 10.1053/j.gastro.2004.12.049 – volume: 41 start-page: 175 year: 2006 ident: R57-1-20210130 article-title: Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients publication-title: J Acquir Immune Defic Syndr doi: 10.1097/01.qai.0000194238.15831.c7 |
| SSID | ssj0005088 |
| Score | 2.3921666 |
| SecondaryResourceType | review_article |
| Snippet | Chronic hepatitis C (HCV) infection is currently one of the most clinically relevant comorbidities in the HIV population; overall, it affects one third of... |
| SourceID | proquest pubmed pascalfrancis crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 1073 |
| SubjectTerms | Anti-HIV Agents - therapeutic use Anti-Retroviral Agents - adverse effects Antiviral Agents - administration & dosage Biological and medical sciences Chemical and Drug Induced Liver Injury Drug Administration Schedule Drug Interactions Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - enzymology HIV Infections - complications HIV Infections - drug therapy HIV Infections - enzymology Human immunodeficiency virus Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Interferons - administration & dosage Liver Cirrhosis - etiology Liver Cirrhosis - pathology Medical sciences Ribavirin - administration & dosage Transaminases - analysis Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral hepatitis |
| Title | Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV–HIV International Panel |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/17502718 https://www.proquest.com/docview/21053769 https://www.proquest.com/docview/70513973 |
| Volume | 21 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEkVPEmBcoeuEWG-G1zi1xQQmhdmgR6i-xdR0Rq46i2OXDgj_HnmNmH7YRUBS5WZK03lufz7nzj-WYIec1d1FdixN20MwP8f26EAcMeGonpe6kDTgjqnY9PvOHM-Xjunnc6v1pZS1WZvmE_dupK_seqcA7siirZf7BsPSmcgN9gXziCheH4VzZG8ZBIWZbFUYsey2Vylc4pHwK5w8j4twyHlMuiF_W-L6-qQkQCMIDYq9bI-VHDAnd4makeS0WjOxlGXwycZzN2eJqsVLK9LmE7Opq0-4PUAYZJfDYanMQioXa5Yq1Em9NZPB1JwRC8mZd5_fEnjsaT6Vk8lLIRoQ-tZ5t9GsdfJ-PRhtBIhy18_cVdhy12lJ8QYYvlBeYGtVZBywsN8KH67SVbiqoVNMPW-gtk1m7t5WZf9if6Y5-Q9Yc_D450INgKYKyTObzZF3UuwNZ2WScxmgGQ-zBwb5HbFnAUwedH4ya_qC-antb3r3Wbof921_9u-EX31kkBr-hC9la5nvwIJ2h6n-wr9kIHEooPSCdbPSR3jlV-xiPyExFJ8wXViKQNIikikgKSKCCS1oikERWIpO8oGpAqPNItPFLEIwU8UoVHuoFHKvD4mMw-vJ9GQ0N1-DCY7Xml4TIPixVx4MwstLEYnAv7Q8pcK0t5EjKfB-BMeYnjpxx4srcAuhH4jC88K0Eubz8he6t8lT0jNPFtlnE43U8cJwmAh2NdocD2Ej8wFyHvEls_3zlT5e-xC8vFXKdhgFXm21bpEqO-ai3Lv9ww_nDDdM1FCixd8krbcg4LOX6dg-eTV8XcMkVppfD6ET5soEAf7C55KkHQzA5-vwVe5sFNf_-c3G1exhdkr7yqspfgVZfpoUDvb8eOxoE |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Care+of+patients+coinfected+with+HIV+and+hepatitis+C+virus+%3A+2007+updated+recommendations+from+the+HCV-HIV+International+Panel&rft.jtitle=AIDS+%28London%29&rft.au=SORIANO%2C+Vincent&rft.au=PUOTI%2C+Massimo&rft.au=ROCKSTROH%2C+Juergen&rft.au=SULKOWSKI%2C+Mark&rft.date=2007-05-31&rft.pub=Lippincott+Williams+%26+Wilkins&rft.issn=0269-9370&rft.volume=21&rft.issue=9&rft.spage=1073&rft.epage=1089&rft_id=info:doi/10.1097%2FQAD.0b013e3281084e4d&rft.externalDBID=n%2Fa&rft.externalDocID=18837985 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-9370&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-9370&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-9370&client=summon |